Back to top
more

Apellis Pharmaceuticals (APLS)

(Delayed Data from NSDQ)

$49.93 USD

49.93
1,222,999

+1.21 (2.48%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $49.85 -0.08 (-0.16%) 6:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates

by Zacks Equity Research

Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Apellis Pharmaceuticals, Inc. (APLS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

The Zacks Analyst Blog Highlights HEICO, Constellation Energy, Inter Parfums, Apellis Pharmaceuticals and Vaxcyte

by Zacks Equity Research

HEICO, Constellation Energy, Inter Parfums, Apellis Pharmaceuticals and Vaxcyte are part of the Zacks top Analyst Blog.

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -10.61% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.

Nalak Das headshot

5 Stocks to Buy That Are Poised to Beat on Earnings This Week

by Nalak Das

We have narrowed our search to five stocks that are poised to beat on earnings this week. These are: HEi, CEG, IPAR, APLS, PCVX.

Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?

by Zacks Equity Research

Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.

Why Apellis (APLS) Might Surprise This Earnings Season

by Zacks Equity Research

Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Apellis Pharmaceuticals, Inc. (APLS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apellis (APLS) Down on Negative CHMP Opinion for Pegcetacoplan

by Zacks Equity Research

Apellis (APLS) stock falls on the CHMP's negative recommendation to the EMA regarding the approval of intravitreal pegcetacoplan in the EU for the treatment of geographic atrophy secondary to age-related macular degeneration.

Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How

by Zacks Equity Research

Annexon (ANNX) has rallied 156% in the past three months on plans to begin a registrational program for ANX007 in GA after reaching FDA alignment on the study's primary endpoint.

Apellis (APLS): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

Apellis (APLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Apellis (APLS) Up on Strong Q4 Preliminary Syfovre U.S. Revenues

by Zacks Equity Research

Apellis (APLS) reports strong preliminary net product revenues in the United States for the fourth quarter of 2023, driven by robust Syfovre sales. The stock gains 15%.

Apellis Pharmaceuticals, Inc. (APLS) Soars 14.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA

by Zacks Equity Research

The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.

Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry

by Zacks Equity Research

Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.

Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead

by Zacks Equity Research

Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.

BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study

by Zacks Equity Research

The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.